After that the era of chemotherapy in the treatment of solid tumors have been overcome by the "translational era", with the innovation introduced by targeted therapies, medical oncology is currently looking ...After that the era of chemotherapy in the treatment of solid tumors have been overcome by the "translational era", with the innovation introduced by targeted therapies, medical oncology is currently looking at the dawn of a new "immunotherapy era" with the advent of immune checkpoint inhibitors(CKI) antibodies.The onset of PD-1/PD-L1 targeted therapy has demonstrated the importance of this axis in the immune escape across almost all human cancers.The new CKI allowed to significantly prolong survival and to generate durable response, demonstrating remarkable efficacy in a wide range of cancer types.The aim of this article is to review the most up to date literature about the clinical effectiveness of CKI antibodies targeting PD-1/PD-L1 axis for the treatment of advanced solid tumors and to explore transversal challenges in the immune checkpoint blockade.展开更多
目的探索酮还原酶家族1成员C3(aldo-keto reductase family 1 member C3,AKR1C3)对乳腺癌恶性细胞生物学行为的干预作用及对程序性细胞死亡蛋白/程序性死亡-配体1(programmed cell death protein1/programmed death-ligand1,PD-1/PD-L)...目的探索酮还原酶家族1成员C3(aldo-keto reductase family 1 member C3,AKR1C3)对乳腺癌恶性细胞生物学行为的干预作用及对程序性细胞死亡蛋白/程序性死亡-配体1(programmed cell death protein1/programmed death-ligand1,PD-1/PD-L)通路的影响。方法把MCF-7人乳腺癌细胞中NC组和AKR1C3组分别转染空质粒和AKR1C3质粒,采用MTT法检测转染后24 h、48 h、72 h细胞活力;采用流式细胞技术测定各组细胞的存活率以及早期、晚期凋亡比例;通过Transwell实验对各组细胞的迁移和侵袭能力进行检测;通过Western blot检测各组细胞PD-1、PD-L1、蛋白激酶B(protein kinase b,AKT)蛋白表达水平。使用C57BL/6小鼠构建荷瘤模型,将采用人乳腺癌MCF-7细胞转染NC质粒和AKR1C3质粒进行细胞荷瘤,每3 d测量瘤体积,持续21 d,绘制两组小鼠肿瘤生长曲线,并于实验终点测量肿瘤质量。结果相较于NC组,AKR1C3组细胞活力降低(P<0.05),并且具有时间依赖效应(P<0.05),迁移和侵袭能力降低(P<0.05),早期凋亡和晚期凋亡比例升高(P<0.05),PD-1、PD-L1、AKT蛋白表达水平降低(P<0.05)。动物实验表明,AKR1C3组小鼠肿瘤体积降低,肿瘤质量下降(P<0.05)。结论AKR1C3可以抑制人乳腺癌细胞恶性生物学行为,抑制PD-1/PDL1信号通路蛋白表达。展开更多
目的约70%接受程序性细胞死亡蛋白1(Programmed Cell Death Protein-1,PD-1)及其配体(Programmed Cell Death Ligand 1,PD-L1)抑制剂治疗的患者会出现免疫相关不良事件(Immune-Related Adverse Events,irAEs)。然而,PD-1/PD-L1抑制剂导...目的约70%接受程序性细胞死亡蛋白1(Programmed Cell Death Protein-1,PD-1)及其配体(Programmed Cell Death Ligand 1,PD-L1)抑制剂治疗的患者会出现免疫相关不良事件(Immune-Related Adverse Events,irAEs)。然而,PD-1/PD-L1抑制剂导致irAEs的机制仍不清楚。方法本研究中,我们从公开的全基因组关联研究(Genome-Wide Association Studies,GWAS)中收集了涉及欧洲血统个体的数据。采用双样本孟德尔随机化(Two-Sample Mendelian Randomization,TSMR)方法探讨了PD-1/PD-L1与免疫相关不良事件之间的因果关系,以及731种免疫细胞、1400种代谢物和41种炎症细胞因子的介导效应。此外,我们还通过敏感性分析来验证结果的异质性和多效性,以加强结果的稳健性。结果我们确定了PD-1/PD-L1与免疫相关不良事件之间的九种因果关系,其中我们发现在常见的irAEs中,PD-1/PD-L1与胃肠道疾病和内分泌腺疾病的水平增加相关,而在其他irAEs中,呼吸系统疾病、精神疾病和免疫系统疾病与PD-1/PD-L1相关。在反向分析中,我们发现抑郁症与PD-L1之间存在显著的因果关系。此外,我们还发现PD-1可通过N-甲基羟脯氨酸水平影响过敏性鼻炎,而PD-L1可通过3-甲基己二酸水平和羟基棕榈酰鞘磷脂(d18:1/16:0(OH))水平影响哮喘。结论MR分析揭示了PD-1/PD-L1与免疫相关不良事件之间的双向因果关系,而这种关系可能是由代谢物介导的。展开更多
Cancer is a global health problem and one of the leading causes of mortality.Immune checkpoint inhibitors have revolutionized the field of oncology,emerging as a powerful treatment strategy.A key pathway that has garn...Cancer is a global health problem and one of the leading causes of mortality.Immune checkpoint inhibitors have revolutionized the field of oncology,emerging as a powerful treatment strategy.A key pathway that has garnered considerable attention is programmed cell death-1(PD-1)/programmed cell death-ligand 1(PD-L1).The interaction between PD-L1 expressed on tumor cells and PD-1 reduces the innate immune response and thus compromises the capability of the body’s immune system.Furthermore,it controls the phenotype and functionality of innate and adaptive immune components.A range of monoclonal antibodies,including avelumab,atezolizumab,camrelizumab,dostarlimab,durvalumab,sinitilimab,toripalimab,and zimberelimab,have been developed for targeting the interaction between PD-1 and PD-L1.These agents can induce a broad spectrum of autoimmune-like complications that may affect any organ system.Recent studies have focused on the effect of various natural compounds that inhibit immune checkpoints.This could contribute to the existing arsenal of anticancer drugs.Several bioactive natural agents have been shown to affect the PD-1/PD-L1 signaling axis,promoting tumor cell apoptosis,influencing cell proliferation,and eventually leading to tumor cell death and inhibiting cancer progression.However,there is a substantial knowledge gap regarding the role of different natural compounds targeting PD-1 in the context of cancer.Hence,this review aims to provide a common connection between PD-1/PD-L1 blockade and the anticancer effects of distinct natural molecules.Moreover,the primary focus will be on the underlying mechanism of action as well as the clinical efficacy of bioactive molecules.Current challenges along with the scope of future research directions targeting PD-1/PD-L1 interactions through natural substances are also discussed.展开更多
Anti-programmed cell death protein 1(PD-1)or its ligand(PD-L1)are immune checkpoint inhibitors(ICIs)that have revolutionized cancer therapy.However,the efficacy of anti-PD-1 and anti-PD-L1 is limited by resistance and...Anti-programmed cell death protein 1(PD-1)or its ligand(PD-L1)are immune checkpoint inhibitors(ICIs)that have revolutionized cancer therapy.However,the efficacy of anti-PD-1 and anti-PD-L1 is limited by resistance and inter-individual variability.In recent years increasing evidence has highlighted the pivotal role of the gut microbiota in modulating the response to PD-1/PD-L1 immunotherapy.Extensive preclinical studies have demonstrated that commensal microbes can increase the efficacy of PD-1/PD-L1 blockade through multiple mechanisms,including the production of metabolites,such as short-chain fatty acids(SCFAs),tryptophan derivatives,and extracellular polysaccharides that remodel the tumor microenvironment,as well as the activation of immune pathways involving dendritic cells,CD8+T cells,and M1 macrophages to increase antitumor immunity.Moreover,clinical studies have shown that fecal microbiota transplantation(FMT)and targeted probiotic interventions show promise for improving the response to PD-1/PD-L1 therapy,while reducing the risk of immune-related adverse events(irAEs).This review systematically explores the multifaceted regulatory roles of the commensal microbiota in PD-1/PD-L1 therapy and examines the preclinical prospects of microbiota-based personalized immunotherapeutic strategies.The integration of multiomics technologies,synthetic biology,and precise microbiota interventions may further optimize PD-1/PD-L1 immunotherapy and offer novel insights into antitumor immune modulation.展开更多
以往的研究主要集中在肿瘤细胞在免疫逃逸中的变化,而对肿瘤微环境(tumor microenvironment, TME)对免疫逃逸的影响知之甚少。肿瘤相关成纤维细胞(tumor-associated fibroblasts, TAFs)是TME的重要组成部分,具有特殊的生理生化特性,但...以往的研究主要集中在肿瘤细胞在免疫逃逸中的变化,而对肿瘤微环境(tumor microenvironment, TME)对免疫逃逸的影响知之甚少。肿瘤相关成纤维细胞(tumor-associated fibroblasts, TAFs)是TME的重要组成部分,具有特殊的生理生化特性,但其具体机制尚不清楚。为了研究TAF对胃癌细胞PD-L1表达的影响,通过transwell将胃癌细胞株MNK45、SGC7901与TAFs非接触共培养1、3、7 d。采用qRT-PCR和流式细胞仪检测PD-L1 mRNA和蛋白表达。然后选择95例胃癌组织,通过免疫组化检测PD-L1和TAFs的表达。结果显示,实验组PD-L1 mRNA和蛋白表达量均显著高于对照组。胃癌中PD-L1的表达与大量淋巴细胞浸润、弥漫性/混合性组织学和瘤内TAFs有关。综上所述,TAFs通过提高PD-L1的表达促进胃癌细胞株的生长。Previous studies have focused on the changes of tumour cells in immune escape, and less is known about the effect of the tumour microenvironment (TME) on immune escape. Tumour-associated fibroblasts (TAFs) cells are an important part of the TME and have special physiological and biochemical characteristics, but the specific mechanism has not been clarified. In order to investigate the effect of TAFs on the expression of PD-L1 in gastric cancer cells, gastric cancer cell lines MNK45, SGC7901 were non-contact coculturing with TAFs 1, 3 and 7 d via transwell. PD-L1 mRNA and protein expression were detected using qRT-PCR and FCM. Then, 95 cases of gastric cancer tissues were selected and PD-L1 and TAFs expressions were determined by immunohistochemical examination. The results showed that the mRNA and protein expression of PD-L1 in the experiment group were significantly higher than that in the control group. PD-L1 expression was associated with massive lymphocyte infiltration, diffuse/mixed histology and intratumoral TAFs in gastric cancers. In conclusion, TAFs promoted the growth of gastric cancer cell lines by increasing the PD-L1 expression.展开更多
目的评价阿帕替尼联合程序性死亡受体1/程序性死亡受体配体1(PD-1/PD-L1)抑制剂治疗恶性实体瘤的有效性与安全性。方法检索PubMed、Web of Science、Embase、Cochrane Library、中国知网、维普网、万方数据、中国生物医学文献数据库,收...目的评价阿帕替尼联合程序性死亡受体1/程序性死亡受体配体1(PD-1/PD-L1)抑制剂治疗恶性实体瘤的有效性与安全性。方法检索PubMed、Web of Science、Embase、Cochrane Library、中国知网、维普网、万方数据、中国生物医学文献数据库,收集阿帕替尼联合PD-1/PD-L1抑制剂和(或)化疗/其他疗法(联合组)对比阿帕替尼或PD-1/PD-L1抑制剂单药和(或)化疗/其他疗法(对照组)治疗恶性实体瘤的随机对照研究(RCT),检索时限为建库至2025年5月。筛选文献、提取资料、评价文献质量后,采用RevMan 5.3和Stata 14.0软件进行Meta分析。结果共纳入28篇RCTs,包括2974例患者。联合组患者的客观缓解率[RR=1.639,95%CI(1.452,1.851),P<0.00001],疾病控制率[RR=1.284,95%CI(1.178,1.399),P<0.00001],CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)以及高血压、疲劳乏力、蛋白尿、血小板减少等不良反应的发生率均显著高于对照组(P<0.05或P<0.00001);疾病进展率[RR=0.497,95%CI(0.437,0.566),P<0.00001]、血清肿瘤标志物水平、CD8^(+)均显著低于对照组(P<0.05或P<0.00001)。不同类型肿瘤的亚组分析结果显示,联合组患者的客观缓解率和疾病控制率均显著高于对照组(P<0.05)。敏感性分析结果显示,本研究结果的稳定性良好。发表偏倚分析结果显示,本研究存在发表偏倚的可能性较大。结论阿帕替尼联合PD-1/PD-L1抑制剂治疗不同类型肿瘤的疗效显著,但需注意高血压、疲劳乏力、蛋白尿、血小板减少的发生。展开更多
文摘After that the era of chemotherapy in the treatment of solid tumors have been overcome by the "translational era", with the innovation introduced by targeted therapies, medical oncology is currently looking at the dawn of a new "immunotherapy era" with the advent of immune checkpoint inhibitors(CKI) antibodies.The onset of PD-1/PD-L1 targeted therapy has demonstrated the importance of this axis in the immune escape across almost all human cancers.The new CKI allowed to significantly prolong survival and to generate durable response, demonstrating remarkable efficacy in a wide range of cancer types.The aim of this article is to review the most up to date literature about the clinical effectiveness of CKI antibodies targeting PD-1/PD-L1 axis for the treatment of advanced solid tumors and to explore transversal challenges in the immune checkpoint blockade.
文摘目的约70%接受程序性细胞死亡蛋白1(Programmed Cell Death Protein-1,PD-1)及其配体(Programmed Cell Death Ligand 1,PD-L1)抑制剂治疗的患者会出现免疫相关不良事件(Immune-Related Adverse Events,irAEs)。然而,PD-1/PD-L1抑制剂导致irAEs的机制仍不清楚。方法本研究中,我们从公开的全基因组关联研究(Genome-Wide Association Studies,GWAS)中收集了涉及欧洲血统个体的数据。采用双样本孟德尔随机化(Two-Sample Mendelian Randomization,TSMR)方法探讨了PD-1/PD-L1与免疫相关不良事件之间的因果关系,以及731种免疫细胞、1400种代谢物和41种炎症细胞因子的介导效应。此外,我们还通过敏感性分析来验证结果的异质性和多效性,以加强结果的稳健性。结果我们确定了PD-1/PD-L1与免疫相关不良事件之间的九种因果关系,其中我们发现在常见的irAEs中,PD-1/PD-L1与胃肠道疾病和内分泌腺疾病的水平增加相关,而在其他irAEs中,呼吸系统疾病、精神疾病和免疫系统疾病与PD-1/PD-L1相关。在反向分析中,我们发现抑郁症与PD-L1之间存在显著的因果关系。此外,我们还发现PD-1可通过N-甲基羟脯氨酸水平影响过敏性鼻炎,而PD-L1可通过3-甲基己二酸水平和羟基棕榈酰鞘磷脂(d18:1/16:0(OH))水平影响哮喘。结论MR分析揭示了PD-1/PD-L1与免疫相关不良事件之间的双向因果关系,而这种关系可能是由代谢物介导的。
基金support provided by the Department of Science and Technology,Science and Engineering Research Board(DST-SERB),the Anusandhan National Research Foundation(ANRF),State University Research Excellence(SERB-SURE),Ministry of Science and Technology,Govt.of India(SUR/2022/001353).
文摘Cancer is a global health problem and one of the leading causes of mortality.Immune checkpoint inhibitors have revolutionized the field of oncology,emerging as a powerful treatment strategy.A key pathway that has garnered considerable attention is programmed cell death-1(PD-1)/programmed cell death-ligand 1(PD-L1).The interaction between PD-L1 expressed on tumor cells and PD-1 reduces the innate immune response and thus compromises the capability of the body’s immune system.Furthermore,it controls the phenotype and functionality of innate and adaptive immune components.A range of monoclonal antibodies,including avelumab,atezolizumab,camrelizumab,dostarlimab,durvalumab,sinitilimab,toripalimab,and zimberelimab,have been developed for targeting the interaction between PD-1 and PD-L1.These agents can induce a broad spectrum of autoimmune-like complications that may affect any organ system.Recent studies have focused on the effect of various natural compounds that inhibit immune checkpoints.This could contribute to the existing arsenal of anticancer drugs.Several bioactive natural agents have been shown to affect the PD-1/PD-L1 signaling axis,promoting tumor cell apoptosis,influencing cell proliferation,and eventually leading to tumor cell death and inhibiting cancer progression.However,there is a substantial knowledge gap regarding the role of different natural compounds targeting PD-1 in the context of cancer.Hence,this review aims to provide a common connection between PD-1/PD-L1 blockade and the anticancer effects of distinct natural molecules.Moreover,the primary focus will be on the underlying mechanism of action as well as the clinical efficacy of bioactive molecules.Current challenges along with the scope of future research directions targeting PD-1/PD-L1 interactions through natural substances are also discussed.
基金supported by grants from the National Natural Science Foundation of China(Grant Nos.82222058,82425046,and 82273142).
文摘Anti-programmed cell death protein 1(PD-1)or its ligand(PD-L1)are immune checkpoint inhibitors(ICIs)that have revolutionized cancer therapy.However,the efficacy of anti-PD-1 and anti-PD-L1 is limited by resistance and inter-individual variability.In recent years increasing evidence has highlighted the pivotal role of the gut microbiota in modulating the response to PD-1/PD-L1 immunotherapy.Extensive preclinical studies have demonstrated that commensal microbes can increase the efficacy of PD-1/PD-L1 blockade through multiple mechanisms,including the production of metabolites,such as short-chain fatty acids(SCFAs),tryptophan derivatives,and extracellular polysaccharides that remodel the tumor microenvironment,as well as the activation of immune pathways involving dendritic cells,CD8+T cells,and M1 macrophages to increase antitumor immunity.Moreover,clinical studies have shown that fecal microbiota transplantation(FMT)and targeted probiotic interventions show promise for improving the response to PD-1/PD-L1 therapy,while reducing the risk of immune-related adverse events(irAEs).This review systematically explores the multifaceted regulatory roles of the commensal microbiota in PD-1/PD-L1 therapy and examines the preclinical prospects of microbiota-based personalized immunotherapeutic strategies.The integration of multiomics technologies,synthetic biology,and precise microbiota interventions may further optimize PD-1/PD-L1 immunotherapy and offer novel insights into antitumor immune modulation.
文摘以往的研究主要集中在肿瘤细胞在免疫逃逸中的变化,而对肿瘤微环境(tumor microenvironment, TME)对免疫逃逸的影响知之甚少。肿瘤相关成纤维细胞(tumor-associated fibroblasts, TAFs)是TME的重要组成部分,具有特殊的生理生化特性,但其具体机制尚不清楚。为了研究TAF对胃癌细胞PD-L1表达的影响,通过transwell将胃癌细胞株MNK45、SGC7901与TAFs非接触共培养1、3、7 d。采用qRT-PCR和流式细胞仪检测PD-L1 mRNA和蛋白表达。然后选择95例胃癌组织,通过免疫组化检测PD-L1和TAFs的表达。结果显示,实验组PD-L1 mRNA和蛋白表达量均显著高于对照组。胃癌中PD-L1的表达与大量淋巴细胞浸润、弥漫性/混合性组织学和瘤内TAFs有关。综上所述,TAFs通过提高PD-L1的表达促进胃癌细胞株的生长。Previous studies have focused on the changes of tumour cells in immune escape, and less is known about the effect of the tumour microenvironment (TME) on immune escape. Tumour-associated fibroblasts (TAFs) cells are an important part of the TME and have special physiological and biochemical characteristics, but the specific mechanism has not been clarified. In order to investigate the effect of TAFs on the expression of PD-L1 in gastric cancer cells, gastric cancer cell lines MNK45, SGC7901 were non-contact coculturing with TAFs 1, 3 and 7 d via transwell. PD-L1 mRNA and protein expression were detected using qRT-PCR and FCM. Then, 95 cases of gastric cancer tissues were selected and PD-L1 and TAFs expressions were determined by immunohistochemical examination. The results showed that the mRNA and protein expression of PD-L1 in the experiment group were significantly higher than that in the control group. PD-L1 expression was associated with massive lymphocyte infiltration, diffuse/mixed histology and intratumoral TAFs in gastric cancers. In conclusion, TAFs promoted the growth of gastric cancer cell lines by increasing the PD-L1 expression.
